Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07073014 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Long-Term Extension Study of Vosoritide to Treat Children With Hypochondroplasia

Study acronym: CANOPY-HCH-EXT
StatusEnrolling by Invitation
PhasePhase 3
Started
View on ClinicalTrials.gov ↗
Trial flagged as At Risk
Primary completion moved at least 3 years 9 months later Dec 2040 → Oct 2044
See other at-risk trials from BioMarin Pharmaceutical

Record History

  1. Primary and study completion pushed from Dec 2040 to Oct 2044
    • Trial sites expanded: 23 → 30 locations
    v2
  2. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
The purpose of this study is to evaluate the long-term safety and efficacy of daily doses of vosoritide in participants with HCH
Trial Details
NCT Number NCT07073014
Lead Sponsor BioMarin Pharmaceutical
Conditions
(from sponsor)		 Hypochondroplasia
Related terms Hypochondroplasia
Enrollment 140 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov